Fungicidal versus Fungistatic: what's in a word?

Bibliography

• Manavathu E. A comparative study of the post-antifungal effect (PAFE) of amphotericin B, triazoles, and echinocandins on Aspergillus fumigatus and Candida albicans. J Antimicrob Chemother 2004;53:386-9
   PubMed Web of Science ®Google Scholar
• Manavathu EK, Cutright JL, Chandrasekar PH. Organism-dependent fungicidal activities of azoles. Antimicrob Agents Chemother 1998;42:3018-21
   PubMed Web of Science ®Google Scholar
• Rubio C, Ramirez De Ocariz I, Gil J, et al. Potential fungicidal effect of voriconazole against Candida spp. Int J Antimicrob Agents 2005;25:264-7
   PubMedGoogle Scholar
• Espinel-Ingroff A. Germinated and nongerminated conidial suspensions for testing of susceptibilities of Aspergillus spp. to amphotericin B, itraconazole, posaconazole, ravuconazole, and voriconazole. Antimicrob Agents Chemother 2001;45:605-7
   PubMed Web of Science ®Google Scholar
• Lass-Florl C, Nagl M, Speth C, et al. Studies of in vitro activities of voriconazole and itraconazole against Aspergillus hyphae using viability staining. Antimicrob Agents Chemother 2001;45:124-8
   PubMed Web of Science ®Google Scholar
• Krishnan S, Manavathu E, Chandrasekar PH. A comparative study of fungicidal activities of voriconazole and amphotericin B against hyphae of Aspergillus fumigatus. J Antimicrob Chemother 2005;55:914-20
   PubMed Web of Science ®Google Scholar
• Bowman JC, Hicks PS, Kurtz MB, et al. The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro. Antimicrob Agents Chemother 2002;46:3001-12
   PubMed Web of Science ®Google Scholar
• Kurtz MB, Heath IB, Marrinan J, et al. Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-β-D-glucan synthase. Antimicrob Agents Chemother 1994;38:1480-9
   PubMed Web of Science ®Google Scholar
• Petraitis V, Petratiene R, Sarafandi AA, et al. Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J Infect Dis 2002;187:1834-43
   Google Scholar
• Bowman JC, Abruzzo GK, Flattery AM, et al. Effect of caspofungin against Aspergillus flavus, Aspergillus terreus, and Aspergillus nidulans. Antimicrob Agents Chemother 2006;50:4202-5
   PubMed Web of Science ®Google Scholar
• Van Vianen W, De Marie S, Ten Kate MT, et al. Caspofungin: antifungal activity in vitro, pharmacokinetics, and effects on fungal load and animal survival in neutropenic rats with invasive pulmonary aspergillosis. J Antimicrob Chemother 2006;57:732-40
   PubMed Web of Science ®Google Scholar
• Bowman JC, Abruzzo GK, Anderson JW, et al. Quantitative PCR assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: demonstration of efficacy of caspofungin acetate. Antimicrob Agents Chemother 2001;45:3474-81
   PubMed Web of Science ®Google Scholar
• Maccallum DM, Whyte JA, Odds FC. Efficacy of caspofungin and voriconazole combinations in experimental aspergillosis. Antimicrob Agents Chemother 2005;49:3697-701
   PubMed Web of Science ®Google Scholar
• Gonzalez G, Tijerina R, Najvar L, et al. Correlation between antifungal susceptibilities of Coccidioides immitis (CI) in vitro and antifungal treatment with caspofungin in a mouse model. Antimicrob Agents Chemother 2001;45:1854-9
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Sheehan DJ, Rex JH. Determination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization. Clin Microbiol Rev 2004;17:268-80
   PubMed Web of Science ®Google Scholar
• Larsen RA, Leal MA, Chan LS. Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS: a randomized trial. Ann Intern Med 1992;113:183-7
   Google Scholar
• Van Der Horst C, Saag M, Cloud G, et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. N Engl J Med 1997;337:15-21
   PubMed Web of Science ®Google Scholar
• Barchiesi F, Schimizzi AM, Caselli F, et al. Interactions between triazoles and amphotericin B against Cryptococcus neoformans. Antimicrob Agents Chemother 2000;44:2435-41
   PubMed Web of Science ®Google Scholar
• Larsen RA, Bauer M, Thomas AM, Graybill JR. Amphotericin B and fluconazole, a potent combination therapy for cryptococcal meningitis. Antimicrob Agents Chemother 2004;48:985-91
   PubMed Web of Science ®Google Scholar
• Brouwer AE, Rajanuwong A, Chierakul W, et al. Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet 2004;363:1764-7
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Diekema DJ, Jones RN, et al. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. J Clin Microbiol 2001;39:3254-9
   PubMed Web of Science ®Google Scholar
• Pappas PG, Rex JH, Sobel JD, et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004;38:161-89
   PubMed Web of Science ®Google Scholar
• Ostrosky-Zeichner L, Marr KA, Rex JH, Cohen SH. Amphotericin B: time for a new ‘gold standard’. Clin Infect Dis 2003;37:415-25
   PubMed Web of Science ®Google Scholar
• Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med 1994;331:1325-30
   PubMed Web of Science ®Google Scholar
• Rex JH, Pappas P, Karchmer AW. A randomized and blinded multicenter-trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in non-neutropenic subjects. Clin Infect Dis 2003;36:1221-8
   PubMed Web of Science ®Google Scholar
• Schaffner A, Frick PG. The effect of ketoconazole on amphotericin B in a model of disseminated aspergillosis. J Infect Dis 1985;151:902-10
   PubMed Web of Science ®Google Scholar
• Kontoyiannis DP, Lewis RE, Sagar N, et al. Itraconazole–Amphotericin B antagonism in Aspergillus fumigatus: an E-test-based strategy. Antimicrob Agents Chemother 2000;44:2915-8
   PubMed Web of Science ®Google Scholar
• Kontoyiannis DP. Why prior fluconazole use is associated with an increased risk of invasive mold infections in immunosuppressed hosts: an alternative hypothesis. Clin Infect Dis 2002;34:1281-3
   PubMedGoogle Scholar
• Kontoyiannis DP, Lewis RE. Toward more effective antifungal therapy: the prospects of combination therapy. Br J Haematol 2004;126:165-75
   PubMed Web of Science ®Google Scholar
• Lewis RE, Prince RA, Chi J, Kontoyiannis DP. Itraconazole preexposure attenuates the efficacy of subsequent amphotericin B therapy in a murine model of acute invasive pulmonary aspergillosis. Antimicrob Agents Chemother 2002;46:3208-14
   PubMed Web of Science ®Google Scholar
• Polak AM, Scholer HJ, Wall M. Combination therapy of experimental candidiasis, cryptococcosis, and aspergillosis in mice. Chemotherapy 1982;28:461-79
   PubMedGoogle Scholar
• Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002;347:2020-9
   PubMed Web of Science ®Google Scholar
• Kuse E, Chetchotisakd P, Da Cunha CA, et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candisosis: a Phase III randomized double-blind trial. Lancet 2007;369:1519-27
   PubMed Web of Science ®Google Scholar
• Reboli A, Rotstein C, Pappas PG, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007;356:2472-82
   PubMed Web of Science ®Google Scholar
• Deresinski SC, Stevens DA. Caspofungin. Clin Infect Dis 2003;36:1445-57
   PubMed Web of Science ®Google Scholar
• Chandrasekar PH, Sobel JD. Micafungin: a new echinocandin. Clin Infect Dis 2006;42:1171-8
   PubMed Web of Science ®Google Scholar
• Patterson TF, Kirkpatrick WR, White M, et al. Invasive aspergillosis – disease spectrum, treatment practices, and outcomes. Medicine 2000;79:250-60
   PubMed Web of Science ®Google Scholar
• Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408-15
   PubMed Web of Science ®Google Scholar
• Patterson TF, Boucher HW, Herbrecht R, et al. Strategy of following voriconazole versus amphotericin B with other licensed antifungal thersapy for primary treatment of invasive aspergillosis: impact of other therapy on outcome. Clin Infect Dis 2005;41:1448-52
   PubMed Web of Science ®Google Scholar
• Smith J, Safdar N, Kansinski V, et al. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 2006;50:1570-2
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007;44:2-12
   PubMed Web of Science ®Google Scholar
• Cornely OA, Maertens J, Bresnik M, et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad Trial). Clin Infect Dis 2007;44:1289-97
   PubMed Web of Science ®Google Scholar
• Lass-Florl C, Speth C, Kofler G, et al. Effect of increasing inoculum sizes of Aspergillus hyphae on MICs and MFCs of antifungal agents by broth microdilution method. Int J Antimicrob Agents 2003;21:229-33
   PubMed Web of Science ®Google Scholar